Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor γ activation

被引:173
作者
Luna-Medina, R
Cortes-Canteli, M
Alonso, M
Santos, A
Martínez, A
Perez-Castillo, A
机构
[1] Univ Autonoma Madrid, CSIC, Inst Invest Biomed, E-28049 Madrid, Spain
[2] Neuropharma SA, Madrid 28760, Spain
[3] Univ Complutense Madrid, Fac Med, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain
关键词
D O I
10.1074/jbc.M414390200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In most neurodegenerative disorders, including multiple sclerosis, Parkinson disease, and Alzheimer disease, a massive neuronal cell death occurs as a consequence of an uncontrolled inflammatory response, where activated astrocytes and microglia and their cytotoxic agents play a crucial pathological role. Current treatments for these diseases are not effective. In the present study we investigate the effect of thiadiazolidinone derivatives, which have been recently suggested to play a role in neurodegenerative disorders. We have found that thiadiazolidinones are potent neuroprotector compounds. Thiadiazolidinones inhibited inflammatory activation of cultured brain astrocytes and microglia by diminishing lipopolysaccharide-induced interleukin 6, tumor necrosis factor alpha, inducible nitric-oxide synthase, and inducible cyclooxygenase type 2 expression. In addition, thiadiazolidinones inhibited tumor necrosis factor-alpha and nitric oxide production and, concomitantly, protected cortical neurons from cell death induced by the cell-free supernatant from activated microglia. The neuroprotective effects of thiadiazolidinones are completely inhibited by the peroxisome proliferator-activated receptor gamma antagonist GW9662. In contrast the glycogen synthase kinase 3 beta inhibitor LiCl did not show any effect. These findings suggest that thiadiazolidinones potently attenuate lipopolysaccharide-induced neuroinflammation and reduces neuronal death by a mechanism dependent of peroxisome proliferator-activated receptor gamma activation.
引用
收藏
页码:21453 / 21462
页数:10
相关论文
共 50 条
[21]   Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor γ [J].
Han, KH ;
Chang, MK ;
Boullier, A ;
Green, SR ;
Li, A ;
Glass, CK ;
Quehenberger, O .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (06) :793-802
[22]  
Heneka MT, 1998, J NEUROCHEM, V71, P88
[23]   PPAR-γ agonists inhibit production of monocyte inflammatory cytokines [J].
Jiang, CY ;
Ting, AT ;
Seed, B .
NATURE, 1998, 391 (6662) :82-86
[24]   Effects of peroxisome proliferator-activated receptor-γ agonists on central nervous system inflammation [J].
Kielian, T ;
Drew, PD .
JOURNAL OF NEUROSCIENCE RESEARCH, 2003, 71 (03) :315-325
[25]   Roles of peroxisome proliferator-activated receptor γ in lipid homeostasis and inflammatory responses of macrophages [J].
Klappacher, GW ;
Glass, CK .
CURRENT OPINION IN LIPIDOLOGY, 2002, 13 (03) :305-312
[26]  
LASSMANN H, 1994, NEUROPATH APPL NEURO, V20, P195
[27]   NO as an autocrine mediator in the apoptosis of activated microglial cells: correlation between activation and apoptosis of microglial cells [J].
Lee, P ;
Lee, J ;
Kim, S ;
Lee, MS ;
Yagita, H ;
Kim, SY ;
Kim, H ;
Suk, K .
BRAIN RESEARCH, 2001, 892 (02) :380-385
[28]   AN ANTIDIABETIC THIAZOLIDINEDIONE IS A HIGH-AFFINITY LIGAND FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA(PPAR-GAMMA) [J].
LEHMANN, JM ;
MOORE, LB ;
SMITHOLIVER, TA ;
WILKISON, WO ;
WILLSON, TM ;
KLIEWER, SA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (22) :12953-12956
[29]   Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice [J].
Lucas, JJ ;
Hernández, F ;
Gómez-Ramos, P ;
Morán, MA ;
Hen, R ;
Avila, J .
EMBO JOURNAL, 2001, 20 (1-2) :27-39
[30]   Anti-inflammatory actions of 15-deoxy-Δ 12,14-prostaglandin J2 and troglitazone -: Evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression [J].
Maggi, LB ;
Sadeghi, H ;
Weigand, C ;
Scarim, AL ;
Heitmeier, MR ;
Corbett, JA .
DIABETES, 2000, 49 (03) :346-355